The U.S. Food and Drug Administration has granted approval to Mimrylo (rusfertide), a newly authorized therapy for adults battling polycythemia vera, a rare hematologic condition marked by excessive red blood cell synthesis. These surplus cells can raise blood viscosity, heightening the likelihood of cardiovascular complications, such as thrombosis, cerebrovascular events, and myocardial infarction. Developed by Takeda Pharmaceuticals America, Inc., Mimrylo replicates hepcidin, a naturally occurring hormone critical for iron homeostasis. By restricting iron availability for erythropoiesis, Mimrylo curtails overproduction of red blood cells and stabilizes hematocrit levels.
Understanding the Therapeutic Mechanism
The drug’s effectiveness and safety were scrutinized in the VERIFY study, a key phase 3 trial encompassing 293 adults with polycythemia vera who exhibited persistent need for phlebotomies despite conventional treatments. Participants were randomly assigned in a 1:1 ratio to receive either Mimrylo or a placebo over 32 weeks. Treatment initiated at 19 mg via subcutaneous injection weekly, with dosage adjustments to sustain hematocrit levels beneath 45%. Success was gauged by the percentage of patients who avoided phlebotomy criteria between weeks 20 and 32. During the study, 76.9% of those receiving Mimrylo remained phlebotomy-free for the 32-week duration, versus 32.9% in the placebo group.
Clinicians generally target a hematocrit level under 45% to mitigate cardiovascular risks. Achieving this often involves phlebotomy, a procedure extracting blood to reduce red cell concentration. Yet some patients continue requiring frequent phlebotomies despite therapy, imposing a persistent health burden. For these individuals, transitioning to a weekly subcutaneous injection represents a meaningful shift in daily management beyond mere clinical metrics.
Agency Perspective on the New Therapy
Dr. Tanya Wroblewski, the head of the Division of Nonmalignant Hematology at the FDA, discussed the approval. She noted that patients managing this disorder face challenges with frequent blood draws. The agency views this new option as a first-in-class treatment with the potential to lower patient burden.
